MIRA INFORM REPORT

 

 

Report Date :

24.09.2012

 

 

IDENTIFICATION DETAILS

 

Name :

S KANT PHARMA PRIVATE LIMITED

 

 

Registered Office :

Plot No. 7, Turbhe, Thane  Belapur Road, Navi Mumbai-400 705, Maharashtra

 

 

Country :

India

 

 

Financials (as on) :

31.03.2011

 

 

Date of Incorporation :

14.06.1983

 

 

Com. Reg. No.:

11-030195

 

 

Capital Investment / Paid-up Capital :

Rs.1.500 Millions

 

 

CIN No.:

[Company Identification No.]

U24239MH1983PTC030195

 

 

Legal Form :

Private Limited Liability Company

 

 

Line of Business :

Manufacturer of Bulk Drugs and Micro bars

 

 

No. of Employees :

100 (Approximately)

 

 

RATING & COMMENTS

 

MIRA’s Rating :

A (63)

 

RATING

STATUS

PROPOSED CREDIT LINE

56-70

A

Financial & operational base are regarded healthy. General unfavourable factors will not cause fatal effect. Satisfactory capability for payment of interest and principal sums

Fairly Large

 

Maximum Credit Limit :

USD 953000

 

 

Status :

Good

 

 

Payment Behaviour :

Regular

 

 

Litigation :

Clear

 

 

Comments :

Subject is a well established and reputed company having fine track.    Trade relations are fair.  Business is active.  Payments are reported as usually correct and as per commitments.

 

The company can be considered normal for business dealings at usual trade terms and conditions.

 

 

NOTES: Any query related to this report can be made on e-mail: infodept@mirainform.com while quoting report number, name and date.

 

 

INDIAN ECONOMIC OVERVIEW

 

India is developing into an open-market economy, yet traces of its past autarkic policies remain. Economic liberalization, including industrial deregulation, privatization of state-owned enterprises, and reduced controls on foreign trade and investment, began in the early 1990s and has served to accelerate the country's growth, which has averaged more than 7% per year since 1997. India's diverse economy encompasses traditional village farming, modern agriculture, handicrafts, a wide range of modern industries, and a multitude of services. Slightly more than half of the work force is in agriculture, but services are the major source of economic growth, accounting for more than half of India's output, with only one-third of its labor force. India has capitalized on its large educated English-speaking population to become a major exporter of information technology services and software workers. In 2010, the Indian economy rebounded robustly from the global financial crisis - in large part because of strong domestic demand - and growth exceeded 8% year-on-year in real terms. However, India's economic growth in 2011 slowed because of persistently high inflation and interest rates and little progress on economic reforms. High international crude prices have exacerbated the government's fuel subsidy expenditures contributing to a higher fiscal deficit, and a worsening current account deficit. Little economic reform took place in 2011 largely due to corruption scandals that have slowed legislative work. India's medium-term growth outlook is positive due to a young population and corresponding low dependency ratio, healthy savings and investment rates, and increasing integration into the global economy. India has many long-term challenges that it has not yet fully addressed, including widespread poverty, inadequate physical and social infrastructure, limited non-agricultural employment opportunities, scarce access to quality basic and higher education, and accommodating rural-to-urban migration.

Source : CIA

 

RBI DEFAULTERS’ LIST STATUS

 

Subject’s name is not enlisted as a defaulter in the publicly available RBI Defaulters’ list.

 

EPF (Employee Provident Fund) DEFAULTERS’’ LIST STATUS

 

Subject’s name is not enlisted as a defaulter in the publicly available EPF (Employee Provident Fund) Defaulters’ list as of 31-03-2012.

 

INFORMATION DENIED

 

MANAGEMENT NON CO –OPERATIVE

 

91-22-66227575

 

LOCATIONS

 

Registered Office / Factory :

Plot No. 7, Turbhe, Thane  Belapur Road, Navi Mumbai-400705, Maharashtra, India

Tel. No.:

91-22-23648882 / 27681505

Fax No. :

91-22-23633900

E-Mail :

eskay@sk1932.com

eskay@skageexports.com

Area :

1,000,000 Sq. ft.

Location :

Owned

 

 

Administrative Office :

3-A, Shivsagar Estate, Dr. Annie Besant Road, Worli, Mumbai-400018, Maharashtra, India

Tel. No.:

91-22-66227575

Fax No.:

91-22-66227600 / 66227500 / 23633900

E-Mail :

anuh@skageexports.com

Area :

25000 Sq. ft.

Location :

Owned

 

 

DIRECTORS

 

As on 27.09.2011

 

Name :

Mr. Samir Jayantilal Shah

Designation :

Director

Address :

Flat No. 3B, Suvas Apartment, Rungta Lane 68, F. Nepeansea Road, Mumbai 400006, Maharashtra, India

Date of Birth/Age :

22.10.1966

Qualification :

B.com

Date of Appointment :

14.03.2007

DIN :

00157396

 

 

Name :

Mr. Bipin Nemchand Shah

Designation :

Managing Director

Address :

27/5, Prakash 1 , 28a Ridge Road, Malabar Hill,

Mumbai-400006, Maharashtra, India

Date of Birth/Age :

07.03.1949

Qualification :

BSC Engineering

Date of Appointment :

16.12.1985

DIN :

00083244

 

 

Name :

Mr. Ketan Lalitkumar Shah

Designation :

Director

Address :

B2/2, Amalfi, 27B, L. D. Ruparel Marg, Malabar Hill, Mumbai-400006, Maharashtra, India

Date of Birth/Age :

26.05.1971

Qualification :

Graduate

Date of Appointment :

07.03.1996

DIN :

00083326

 

 

Name :

Mr. Lalitkumar Popatlal Shah

Designation :

Director

Address :

B2/2, Amalfi, 27/B, L. D. Ruparel Marg, Malabar Hill, Mumbai-400006, Maharashtra, India

Date of Birth/Age :

02.10.1936

Qualification :

BSC

Date of Appointment :

31.03.1998

DIN :

00396345

 

 

MAJOR SHAREHOLDERS / SHAREHOLDING PATTERN

 

As on 27.09.2011

 

Names of Shareholders

 

No. of Shares

Jayantilal Popatlal Shah

 

270

Lalitkumar Popatlal Shah

 

1200

Japosha Investments and Traders Private Limited, India

 

4530

L. P. Shah Holdings and Traders Private Limited, India

 

7500

Mrudula Jayantilal Shah

 

900

Samir Jayantilal Shah

 

300

Ketan Lalitkumar Shah

 

300

Total

 

15000

 

 

As on 27.09.2011

 

Equity Share Break up

Category

 

Percentage

Bodies corporate

 

80.20

Directors or relatives of directors

 

19.80

Total

 

100.00

 

 

BUSINESS DETAILS

 

Line of Business :

Manufacturer of Bulk Drugs and Micro bars

 

 

PRODUCTION STATUS [As on 31.03.2010]

 

Particulars

Unit

Installed Capacity

Actual Production

Pharmaceutical Bulk Drugs 

Kgs.

420000

234420.28

Pharmaceutical Formulations

 

- Microbar Solids

Kgs.

120000

69415.64

- Microbar Liquids

Ltr.

72000

49110.25

Chemicals

 

- Selenium Sulphide

Kgs.

30000

4487.00

- Methyl Iodide / TMSI

Kgs.

240000

123726.50

 

 

GENERAL INFORMATION

 

Customers :

  • End Users
  • OEM’s

 

 

No. of Employees :

100 (Approximately)

 

 

Bankers :

Ø  Bank of India, Worli Naka Branch , Pankaj Mansion , Opposite Podar Hospital, Dr. A. B. Road , Worli Naka, Mumbai – 400018, Maharashtra, India

Ø  ICICI Bank Limited

 

 

Facilities :

Cash Credit – Rs.150.000 Millions

 

Particulars

31.03.2011

(Rs. In Millions)

31.03.2010

(Rs. In Millions)

Secured Loans

 

 

From Bank of India

 

 

Bank Overdraft (secured against Term Deposits)

5.087

4.992

Total

5.087

4.992

 

Banking Relations :

--

 

 

Auditors :

 

Name :

Chokshi and Chokshi Associates

Chartered Accountants

Address :

15/17, Raghavji B Building, Ground Floor, Raghavi Road, Gowalia Tank, Off KEMPS Corner, Mumbai-400036, Maharashtra, India

Tel. No.:

91-22-23836900

Pan No. :

AAAFC2633B

 

 

Associates : [As on 31.03.2010]

·       S. Kant Healthcare Limited

·       S. Kant Private Limited

·       Sevatilal Kantilal and Company

·       Bharti and Company

·       Anuh Pharma Limited

·       L. P. Shah Holding and Traders Private Limited

·       S. K. Distributors

·       S. K. Age Exports

·       Eskay Specialty Chemicals

 


 

CAPITAL STRUCTURE

 

As on 27.09.2011

 

Authorised Capital :

No. of Shares

Type

Value

Amount

 

 

 

 

25,000

Equity Share

Rs.100/- Each

Rs. 2.500 Millions

 

 

 

 

 

Issued, Subscribed & Paid-up Capital :

No. of Shares

Type

Value

Amount

 

 

 

 

15,000

Equity Share

Rs.100/- Each

Rs. 1.500 Millions

 

 

 

 

 


 

FINANCIAL DATA

[All figures are in Rupees Millions]

 

ABRIDGED BALANCE SHEET

 

SOURCES OF FUNDS

 

31.03.2011

31.03.2010

31.03.2009

SHAREHOLDERS FUNDS

 

 

 

1] Share Capital

1.500

1.500

1.500

2] Share Application Money

0.000

0.000

0.000

3] Reserves & Surplus

236.770

209.243

186.873

4] (Accumulated Losses)

0.000

0.000

0.000

NETWORTH

238.270

210.743

188.373

LOAN FUNDS

 

 

 

1] Secured Loans

5.087

4.992

0.025

2] Unsecured Loans

0.000

0.000

0.000

TOTAL BORROWING

5.087

4.992

0.025

DEFERRED TAX LIABILITIES

0.000

0.223

0.231

 

 

 

 

TOTAL

243.357

215.958

188.629

 

 

 

 

APPLICATION OF FUNDS

 

 

 

 

 

 

 

FIXED ASSETS [Net Block]

29.537

31.931

36.090

Capital work-in-progress

0.201

0.000

0.000

 

 

 

 

INVESTMENT

83.706

48.135

65.000

DEFERREX TAX ASSETS

0.089

0.000

0.000

 

 

 

 

CURRENT ASSETS, LOANS & ADVANCES

 

 

 

 

Inventories

51.728
34.414
60.748

 

Sundry Debtors

133.720
133.158
79.428

 

Cash & Bank Balances

55.268
68.482
66.042

 

Other Current Assets

11.598
5.309
0.641

 

Loans & Advances

42.978
26.932
19.047

Total Current Assets

295.292
268.295
225.906

Less : CURRENT LIABILITIES & PROVISIONS

 
 

 

 

Sundry Creditors

147.791
117.633
135.976

 

Current Liabilities

0.434
1.660
0.264

 

Provisions

17.243
13.109
2.127

Total Current Liabilities

165.468
132.402
138.367

Net Current Assets

129.824
135.893
87.539

 

 

 

 

MISCELLANEOUS EXPENSES

0.000

0.000

0.000

 

 

 

 

TOTAL

243.357

215.958

188.629

 

 

 

PROFIT & LOSS ACCOUNT

 

 

PARTICULARS

31.03.2011

31.03.2010

31.03.2009

 

SALES

 

 

 

 

 

Income

593.992

418.272

508.018

 

 

Other Income

53.498

29.729

11.557

 

 

TOTAL                                     (A)

647.490

448.001

519.575

 

 

 

 

 

Less

EXPENSES

 

 

 

 

 

Cost of Material Sold

3.709

7.015

39.853

 

 

Manufacturing Expenses

543.690

362.883

382.547

 

 

Administrative, Selling and Other Expenses

51.580

36.731

44.817

 

 

TOTAL                                     (B)

598.979

406.629

467.217

 

 

 

 

 

 

PROFIT BEFORE INTEREST, TAX, DEPRECIATION AND AMORTISATION (A-B)     (C)

48.511

41.372

52.358

 

 

 

 

 

Less

FINANCIAL EXPENSES                                    (D)

0.063

1.358

0.310

 

 

 

 

 

 

PROFIT BEFORE TAX, DEPRECIATION AND AMORTISATION (C-D)                                       (E)

48.448

40.014

52.048

 

 

 

 

 

Less/ Add

DEPRECIATION/ AMORTISATION                     (F)

4.391

4.891

5.291

 

 

 

 

 

 

Prior Period Expenses

0.088

0.006

0.000

 

 

 

 

 

 

PROFIT BEFORE TAX (E-F)                              (G)

43.969

35.117

46.757

 

 

 

 

 

Less

TAX                                                                  (H)

14.688

10.992

16.761

 

 

 

 

 

 

PROFIT AFTER TAX (G-H)                                (I)

29.281

24.125

29.996

 

 

 

 

 

 

EARNINGS IN FOREIGN CURRENCY

 

 

 

 

 

FOB Value of Exports

-

108.395

238.855

 

TOTAL EARNINGS

NA

108.395

238.855

 

 

 

 

 

 

IMPORTS

 

 

 

 

 

Raw Materials

-

257.227

308.888

 

 

Packing materials

-

0.000

2.186

 

 

Trading materials

-

0.000

35.570

 

TOTAL IMPORTS

NA

257.227

346.644

 

 

 

 

 

 

Earnings Per Share (Rs.)

1952.07

1608.37

1999.71

 

 


KEY RATIOS

 

PARTICULARS

 

 

31.03.2011

31.03.2010

31.03.2009

PAT / Total Income

(%)

4.52

5.39

5.77

 

 

 

 

 

Net Profit Margin

(PBT/Sales)

(%)

7.40

8.40

9.20

 

 

 

 

 

Return on Total Assets

(PBT/Total Assets}

(%)

13.54

11.70

17.85

 

 

 

 

 

Return on Investment (ROI)

(PBT/Networth)

 

0.18

0.17

0.25

 

 

 

 

 

Debt Equity Ratio

(Total Liability/Networth)

 

0.71

0.65

0.73

 

 

 

 

 

Current Ratio

(Current Asset/Current Liability)

 

1.78

2.03

1.63

 

 

LOCAL AGENCY FURTHER INFORMATION

 

Check List by Info Agents

Available in Report [Yes/No]

Year of Establishment

Yes

Locality of the Firm

Yes

Constitution of the firm

Yes

Premises details

Yes

Type of Business

Yes

Line of Business

Yes

Promoters background

Yes

No. of Employees

Yes

Name of Person Contacted

No

Designation of contact person

No

Turnover of firm for last three years

Yes

Profitability for last three years

Yes

Reasons for variation <> 20%

-

Estimation for coming financial year

No

Capital the business

Yes

Details of sister concerns

Yes

Major Suppliers

No

Major Customers

No

Payment Terms

No

Export / Import Details [If Applicable]

No

Market Information

-

Litigations that the firm / promoter involved in

-

Banking Details

Yes

Banking Facility Details

Yes

Conduct of the banking account

-

Buyer visit details

-

Financials, if provided

Yes

Incorporation details, if applicable

Yes

Last accounts filed at ROC

Yes

Major Shareholders, if applicable

Yes

Date of Birth of Proprietor/Partner/Director, if available

Yes

PAN of Proprietor/Partner/Director, if available

No

Voter ID No of Proprietor/Partner/Director, if available

No

External Agency Rating, if available

No

 

SUNDRY CREDITORS DETAILS:

(Rs. In Millions)

Particulars

31.03.2011

31.03.2010

31.03.2009

 

 

 

 

Due to SSI Undertakings

2.617
3.634
5.098

Due to Others

145.174
113.999
130.878

 

 
 
 

Total

147.791
117.633
135.976

 

OPERATIONS

 

During the year, the company’s turnover has increased from Rs.448.000 Millions to Rs.647.500 Millions i.e. around 44.53% as compared to the previous year. The profit before tax is showing the increasing trend as compared to the last year. The net profit after tax have increased from Rs.24.100 millions to 29.300 millions i.e. by around 21.58% the directors expect continued good results for the next year.

 

Bankers Charges Report as per Registry

 

Corporate identity number of the company

U24239MH1983PTC030195

Name of the company

S KANT PHARMA PRIVATE LIMITED

Address of the registered office or of the principal place of  business in India of the company

Plot No.7, Turbhe-Thane Belapur Road, Belapur Road, Navimumbai – 400705, Maharashtra, India

This form is for

Modification of charge

Charge identification (ID) number of the charge to be modified

90226868

Type of charge

Immovable Property

Any Interest in immovable property

Particular of charge holder

Bank of India, Worli Naka Branch , Pankaj Mansion , Opposite Podar Hospital, Dr. A. B. Road , Worli Naka, Mumbai – 400018, Maharashtra, India

Email : WorliNaka.MumbaiSouth@bankofindia.co.in

Nature of instrument creating charge

Extension of Equitable Mortgage- Oral Assent

Date of instrument Creating the charge

11.04.2011

Amount secured by the charge

Rs.185.000 millions

Brief of the principal terms an conditions and extent and operation of the charge

Rate of Interest - Interest at such rate of interest with monthly/quarterly rests as notified by the Bank from time to time.

 

Terms of Repayment - On Demand

 

Margin - As required by the Bank from time to time.

 

Extent and Operation of the charge - Security in favour of Bank for due repayment by company to Bank at Worli Naka Br. of the facilities aggregating Rs.185.000 millions with interest at agreed rates of interest, security shall remain and continue for any advance of any nature now due or pending or that may be made or become due hereafter from time to time either in the said accounts  or in any other account/s and whether singly or jointly with another or others and whether at Worli Naka Branch or any other branch or

 

Others - office of Bank and/or for any indebtedness or liability whatsoever and for all costs, charges and expenses whatsoever paid or incurred by Bank. Revised Limits of Eskay Fine Chemicals Prop. S Kant Pharma Private Limited: Rs.185.000 millions.

Short particulars of the property or asset(s) charged (including complete address and location of the property)

Equitable Mortgage of the immovable properties of Company consisting of land and building, fixed machinery, plant and fixtures, fittings (both present and future) situate at Plot No. 7 and 7 A Trans Thane Creek Industrial Area, Village Pawne, Taluka Turbhe, Registration Sub District Thane, District and Registration District Thane. Area: 10268 square meters., Tenure: 95 years leasehold.

Date of instrument modifying the charge

24.04.2007

Particulars of the present modification

By this Modification, The principal amount of charge on mortgaged property is enhanced to Rs.185.000 millions. Revised Limits of Eskay Fine Chemicals Prop. S Kant Pharma Private Limited : Rs.185.000 millions.

 

 

This form is for

Modification of charge

Charge identification number of the modified 

90229344

Corporate identity number of the company

U24239MH1983PTC030195

Name of the company

S KANT PHARMA PRIVATE LIMITED

Address of the registered office or of the principal place of  business in India of the company

Plot No. 7, Turbhe, Thane  Belapur Road, Navi Mumbai-400 705, Maharashtra, India

Type of charge

Any interest in immovable property

Particular of charge holder

Bank of India, Worli Naka Branch , Pankaj Mansion , Opposite Podar Hospital, Dr. A B Road , Worli Naka, Mumbai - 400018, Maharashtra, India

Email ID: boiworlinbr@mtnl.net.in 

Nature of description of the instrument creating or modifying the charge

Record of extension of Equitable Mortgage

Date of instrument Creating the charge

24.04.2007

Amount secured by the charge

Rs. 150.000 Millions

Brief particulars of the principal terms an conditions and extent and operation of the charge

Rate of Interest

Interest at such rate of interest with monthly/quarterly rests as notified to them by the Bank from time to time.

 

Terms of Repayment

On Demand

 

Margin

As required by the Bank from time to time.

 

Extent and Operation of the charge

Security in favour of Bank for due repayment by company to Bank at Worli Naka Branch of the said facilities aggregating Rs.150.000 Millions  with interest at agreed rates of interest, security shall remain and continue for any advance of any nature now due or pending or that may be made or become due hereafter from time to time either in the said accounts  or in any other account/s and whether singly or jointly with another or others and whether at Worli Naka Branch or any other branch or

 

Others

Office of Bank and /or for any indebtedness or liability whatsoever and for all costs, charges and expenses whatsoever paid or incurred by Bank. Revised Facilities and Limits of Eskay Fine Chemicals Property S Kant Pharma Private Limited :( Rs.in Millions) FB (A) 1.C/C stocks Rs.10.000 Millions 2. EPC Rs.10.000 Millions Maximum 1 and 2 Rs.10.000 Millions 3.C/C BD Rs.10.000 Millions 4. Inland BP/BD (90 days) NIL, 5.FBP/FBN (DP/DA 150 days) Rs.10.000 Millions Max (3, 4 and 5) Rs.100, Total (A) Rs.10.000 Millions NFB (B) 1. Imp LC(DP/DA180 Days) Rs.139.000 Millions 2.In/Fgn. Gtee Rs.1.000 Million Total (B) Rs.140.000 Millions Total (A+B) Rs.1500.

Short particulars of the property charged

Equitable Mortgage of the Company’s immovable properties consisting of land and building, fixed machinery, plant and fixtures, fittings (both present and future) situate at Plot No. 7 and 7 A Trans Thane Creek Industrial Area, Village Pawne, Taluka Turbhe, Registration Sub District Thane, District and Registration District Thane.

Area: 10268 square meters. Tenure: 95 years leasehold.

Date of latest modification prior to the present modification

13.02.2006

Particulars of the present modification 

The Charge holder's (Bank of India) address is changed from Opera House Br. to its Worli Naka Br.and The charge on the mortgaged property is increased from Rs.85.000 millions to Rs.150.000 millions.

 

Fixed Assets

  • Office Premises
  • Factory Building
  • Plant and Machinery
  • Laboratory and Research Equipment
  • Material Storage and Handling Equipments
  • Electrical Installation
  • Furniture and fixture
  • Office Equipment
  • Vehicle
  • Motor Car

 

 


CMT REPORT (Corruption, Money Laundering & Terrorism]

 

The Public Notice information has been collected from various sources including but not limited to: The Courts, India Prisons Service, Interpol, etc.

 

1]         INFORMATION ON DESIGNATED PARTY

No exist designating subject or any of its beneficial owners, controlling shareholders or senior officers as terrorist or terrorist organization or whom notice had been received that all financial transactions involving their assets have been blocked or convicted, found guilty or against whom a judgement or order had been entered in a proceedings for violating money-laundering, anti-corruption or bribery or international economic or anti-terrorism sanction laws or whose assets were seized, blocked, frozen or ordered forfeited for violation of money laundering or international anti-terrorism laws.

 

2]         Court Declaration :

No records exist to suggest that subject is or was the subject of any formal or informal allegations, prosecutions or other official proceeding for making any prohibited payments or other improper payments to government officials for engaging in prohibited transactions or with designated parties.

 

3]         Asset Declaration :

No records exist to suggest that the property or assets of the subject are derived from criminal conduct or a prohibited transaction.

 

4]         Record on Financial Crime :

            Charges or conviction registered against subject:                                                           None

 

5]         Records on Violation of Anti-Corruption Laws :

            Charges or investigation registered against subject:                                                        None

 

6]         Records on Int’l Anti-Money Laundering Laws/Standards :

            Charges or investigation registered against subject:                                                        None

 

7]         Criminal Records

No available information exist that suggest that subject or any of its principals have been formally charged or convicted by a competent governmental authority for any financial crime or under any formal investigation by a competent government authority for any violation of anti-corruption laws or international anti-money laundering laws or standard.

 

8]         Affiliation with Government :

No record exists to suggest that any director or indirect owners, controlling shareholders, director, officer or employee of the company is a government official or a family member or close business associate of a Government official.

 

9]         Compensation Package :

Our market survey revealed that the amount of compensation sought by the subject is fair and reasonable and comparable to compensation paid to others for similar services.

 

10]        Press Report :

            No press reports / filings exists on the subject.

 


 

CORPORATE GOVERNANCE

 

MIRA INFORM as part of its Due Diligence do provide comments on Corporate Governance to identify management and governance. These factors often have been predictive and in some cases have created vulnerabilities to credit deterioration.

 

Our Governance Assessment focuses principally on the interactions between a company’s management, its Board of Directors, Shareholders and other financial stakeholders.

 

CONTRAVENTION

 

Subject is not known to have contravened any existing local laws, regulations or policies that prohibit, restrict or otherwise affect the terms and conditions that could be included in the agreement with the subject.

 

 

FOREIGN EXCHANGE RATES

 

Currency

Unit

Indian Rupees

US Dollar

1

Rs.53.91

UK Pound

1

Rs.87.60

Euro

1

Rs.70.01

 

INFORMATION DETAILS

 

 

Report Prepared by :

BYI

 

 

SCORE & RATING EXPLANATIONS

 

SCORE FACTORS

 

RANGE

POINTS

HISTORY

1~10

7

PAID-UP CAPITAL

1~10

7

OPERATING SCALE

1~10

7

FINANCIAL CONDITION

 

 

--BUSINESS SCALE

1~10

8

--PROFITABILIRY

1~10

6

--LIQUIDITY

1~10

7

--LEVERAGE

1~10

7

--RESERVES

1~10

7

--CREDIT LINES

1~10

7

--MARGINS

-5~5

--

DEMERIT POINTS

 

 

--BANK CHARGES

YES/NO

YES

--LITIGATION

YES/NO

NO

--OTHER ADVERSE INFORMATION

YES/NO

NO

MERIT POINTS

 

 

--SOLE DISTRIBUTORSHIP

YES/NO

NO

--EXPORT ACTIVITIES

YES/NO

YES

--AFFILIATION

YES/NO

YES

--LISTED

YES/NO

NO

--OTHER MERIT FACTORS

YES/NO

YES

TOTAL

 

63

 

This score serves as a reference to assess SC’s credit risk and to set the amount of credit to be extended. It is calculated from a composite of weighted scores obtained from each of the major sections of this report. The assessed factors and their relative weights (as indicated through %) are as follows:

 

Financial condition (40%)            Ownership background (20%)                  Payment record (10%)

Credit history (10%)                   Market trend (10%)                                Operational size (10%)

 

RATING EXPLANATIONS

 

RATING

STATUS

 

 

PROPOSED CREDIT LINE

>86

Aaa

Possesses an extremely sound financial base with the strongest capability for timely payment of interest and principal sums

 

Unlimited

71-85

Aa

Possesses adequate working capital. No caution needed for credit transaction. It has above average (strong) capability for payment of interest and principal sums

 

Large

56-70

A

Financial & operational base are regarded healthy. General unfavourable factors will not cause fatal effect. Satisfactory capability for payment of interest and principal sums

 

Fairly Large

41-55

Ba

Overall operation is considered normal. Capable to meet normal commitments.

 

Satisfactory

26-40

B

Capability to overcome financial difficulties seems comparatively below average.

 

Small

11-25

Ca

Adverse factors are apparent. Repayment of interest and principal sums in default or expected to be in default upon maturity

 

Limited with full security

<10

C

Absolute credit risk exists. Caution needed to be exercised

 

 

Credit not recommended

-

NB

                                       New Business

-

 

 

 

PRIVATE & CONFIDENTIAL : This information is provided to you at your request, you having employed MIPL for such purpose. You will use the information as aid only in determining the propriety of giving credit and generally as an aid to your business and for no other purpose. You will hold the information in strict confidence, and shall not reveal it or make it known to the subject persons, firms or corporations or to any other. MIPL does not warrant the correctness of the information as you hold it free of any liability whatsoever. You will be liable to and indemnify MIPL for any loss, damage or expense, occasioned by your breach or non observance of any one, or more of these conditions

This report is issued at your request without any risk and responsibility on the part of MIRA INFORM PRIVATE LIMITED (MIPL) or its officials.